Therapeutic efficacy of sulfadoxine-pyrimethamine for Plasmodium falciparum malaria: A study 5 years after implementation of combination therapy in Mpumalanga, South Africa

South African Medical Journal

Volumn 95, Issue 5, 2005, Pages 346-349

  Mabuza, Aaron ^a   Govere, John ^b   la Grange, Kobus ^a   Mngomezulu, Nicros ^a   Allen, Elizabeth ^c   Zitha, Alpheus ^a   Mbokazi, Frans ^a   Durrheim, David ^d   Barnes, Karen ^c  

^a DEPARTMENT OF HEALTH   (South Africa)

^b WORLD HEALTH ORGANIZATION   (Switzerland)

^c UNIVERSITY OF CAPE TOWN   (South Africa)

^d JAMES COOK UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ARTESUNATE; FANSIDAR;

ADOLESCENT; ADULT; ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; DRUG EFFICACY; DRUG RESPONSE; DRUG SENSITIVITY; DRUG USE; FEMALE; FOLLOW UP; GAMETOCYTE; HUMAN; IN VIVO STUDY; INFECTION RESISTANCE; MAJOR CLINICAL STUDY; MALARIA FALCIPARUM; MALE; MAXIMUM PERMISSIBLE DOSE; OPEN STUDY; PARASITE TRANSMISSION; PATIENT MONITORING; PLASMODIUM FALCIPARUM; POLYMERASE CHAIN REACTION; PREVALENCE; PRIMARY HEALTH CARE; SIDE EFFECT; SINGLE DRUG DOSE; SOUTH AFRICA; TREATMENT FAILURE;

ADOLESCENT; ADULT; ANIMALS; ANTIMALARIALS; CHILD; DRUG COMBINATIONS; FEMALE; HUMANS; MALARIA, FALCIPARUM; MALE; PLASMODIUM FALCIPARUM; PREVALENCE; PYRIMETHAMINE; SOUTH AFRICA; SULFADOXINE; TREATMENT OUTCOME;

EID: 20044370826     PISSN: 02569574     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Marsh K. Malaria disaster in Africa. Lancet 1998; 352: 924.
2. Fugh S, Jepson S, Effersoe P. Chloroquine-resistant Plasmodium falciparum in Kenya. Trans R Soc Trop Med Hyg 1979; 73: 228-229.
3. Visagie NJ, Sieling WL. Chloroquine-resistant Plasmodium falciparum malaria in South Africa. S Afr Med J 1985; 68: 600-601.
4. World Health Organisation. Assessment of Therapeutic Efficacy of Antimalarial Drugs, for Uncomplicated Malaria in Areas with Intense Transmission. Geneva: WHO, 1996.
5. Govere JM, la Grange JJ, Durrheim DN, et al. Sulfadoxine-pyrimethamine effectiveness against Plasmodium falciparum malaria in Mpumalanga Province, South Africa. Trans R Soc Trop Med Hyg 1999; 93: 644.
6. Mabuza A, Govere J, Durrheim DN, et al. Therapeutic efficacy of sulfadoxine-pyrimethamine in uncomplicated Plasmodium falciparum malaria 3 years after introduction in Mpumalanga. S Afr Med J 2001; 91: 975-978.
7. Plowe CV, Kublin JG, Dzinjalmala FK, et al. Sustained clinical efficacy of sulfadoxine-pyrimethamine for uncomplicated falciparum malaria after 10 years as first line treatment: five year prospective study. BMJ 2004; 328: 545-548.
8. International Artemisinin Study Group. Artesunate combinations for treatment of malaria; meta-analysis Lancet 2004; 363: 9-17.
9. Nosten F, van Vugt M, Price R, et al. Effects of artesunate mefloquine combination on incidence of Plasmodium falciparum malaria and mefloquine resistance in Western Thailand; a prospective study. Lancet 2000; 356: 297-302.
10. World Health Organization. Assessment and Monitoring of Antimalarial Drug Efficacy for the Treatment of Uncomplicated Falicparum Malaria. Geneva: WHO, 2003.
11. Randford-Cartwright LC, Taylor J, Umasanthar T. Molecular analysis of recrudescent parasites in a Plasmodium falciparum drug efficacy trial in Gabon. Trans R Soc Trop Med Hyg 1997; 91: 719-724.
12. Bredenkamp BL, Sharp BL, Mthembu SD, Durrheim DM, Barnes KI. Failure of sulfadoxine pyrimathamine in treating Plasmodium falciparum malaria in ZwaZulu-Natal. S Afr Med J 2001; 91: 970-972.
13. White NJ, Olliaro PL. Stategies for the prevention of antimalarial drug resistance rationale for combination chemotherapy for malaria. Parasitology Today 1996; 12: 10.
14. Durrheim DN, Sharp BL, Barnes K. Sentinel malaria surveillance: more than a research tool. S Afr Med J 2001; 91: 968-970.
15. Price RN, Nosten F, Luxemburger C, et al. Effects of artemisinin derivatives on malaria transmissbility. Lancet 1996; 347: 1654-1658.